A UK technology company, with offices in the US, has designed, developed and manufactured a bioimpedance device that detects the inherent qualities of cell membranes, through the use of bio-impedance technology. The device is approved by FDA and has CE marking approval pending. The company is looking for an experienced pharmaceutical partner who could use their device to validate their phase 1 and phase 2 trials under a license/services agreement.
A UK technology company has developed a device that detects the inherent qualities of cell membranes through the use of bio-impedance technology. The technology behind the device is bio-impedance and allows a thorough understanding of the cellular membranes of organisms, humans, animals or plants. The device could be used as a clinical tool globally to: - provide the early prognosis of whether a treatment or drug is effective or not - assess the changes in hydration and nutrition in a patient - become an early prognosis tool to show whether an ulcerated wound is healing The medical device is the size of a large smart phone, battery operated and uses the latest in nanotechnology and software filtering to give an industry-leading device. The device currently has applications for wound care healing prognosis, nutrition status in patients and fluid assessments in breast cancer patients. The company is looking for an experienced pharmaceutical partner who could use their device to validate their phase 1 and phase 2 trials under a license/services agreement.
Innovations and advantages
Compared to other similar product, the company's device is smaller, faster, provides more accurate information and has been designed using nanotechnology and the latest in space age signal to noise software filtering; The product is more cost effective than other devices and is manufactured for a fraction of typical research products. The product has full FDA Class II device clearance. The company is now working on obtaining CE Marking approval. The assessment of the individual is NON-INVASIVE so there is a potential for the continuous monitoring of the patient through the simple placing of ECG electrodes on the body. Assessment of the healing of wounds has been carried out with the device as well as nutrition and hydration status in patients. The product is currently being used to assess the fluid retention in breast cancer patients.
Market application codes
05001007 Other diagnostic
05004001 Electromedical and medical equipment
05004004 Medical instruments
Area of partner's activity
The company is looking for an experienced pharmaceutical partner who could use their device to validate their phase 1 and phase 2 trials under a license/services agreement. They are expected to collate data from the device to demonstrate whether a drug or treatment is effective in a patient. Ideally, the business partner sought develops products that would impact the nutritional and hydration of cellular membranes, as the device would be sensitive to those changes. This will allow a prognosis to be identified sooner, before there is a physical change in the patient or obtaining data from other invasive techniques.